NCT00960089

Efficacy Study of LIQUICURE™ to Treat Toe Nail Fungus

Evaluation of the Efficacy of Chesson Labs LIQUICURE™ for Treatment of Onychomycosis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Chesson Laboratory Associates, Inc · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

There is a major clinical need for an inexpensive topically-applied product that can inhibit the growth of the dermatophytes that cause nail fungus. Chesson Labs has developed LIQUICURE with a longer drying/curing time that will allow better nail penetration or adsorption. Though the product may have inherent antimicrobial activity, the product does not contain a drug or antimicrobial agent. Consistent use of LIQUICURE as described will clear fungal nail infection. Clearing of nail fungal infection is defined by negative dermatophyte culture and visual improvement in nail characteristics within six months, with few, if any product-related adverse events.

Conditions

• Onychomycosis

Interventions

Type	Name	Description
DEVICE	LIQUICURE	Topical treatment, 1 time/day, 5 days/week

Timeline

• Start date: 2008-07-01
• Primary completion: 2010-04-01
• Completion: 2010-10-01
• First posted: 2009-08-17
• Last updated: 2016-01-27

Locations

4 sites across 1 country: United States